Terumo Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TRUMF | MDT | BSX | AORT | EW | PEN | |
|---|---|---|---|---|---|---|
| Market cap | 20.47B | 121.20B | 64.33B | 1.06B | 49.92B | 12.64B |
| P/E (TTM) | 19.3 | 23.3 | 18.0 | — | 51.5 | 78.8 |
| Forward P/E | — | 14.8 | 13.1 | 29.1 | 25.6 | 52.3 |
| Price/book | 1.9 | 2.4 | 2.6 | 2.4 | 4.7 | 8.3 |
| Dividend yield | 1.64% | 3.04% | — | — | — | — |
| 1-year change | −18.78% | −1.22% | −55.84% | −48.89% | +15.02% | +29.58% |
| Today | 0.00% | −0.73% | +0.57% | −0.41% | −1.70% | −0.11% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All TRUMF news ›Terumo announces global commercial launch of K-pack Embrace Active safety needle
Manufacturing Chemist Terumo Corporation (TSE: 4543) today announced the global commercial launch of its K-Pack Embrace Active safety needle. The new safety injection needle is packaged in a rigid cap and case container, designed to…
Japan Earnings Wrap: Pan Pacific International, Terumo Decline
Japanese stocks reporting earnings declined on Wednesday, with retailers and thermometer manufacturers leading the laggards. Pan Pacific International Holdings shares tumbled nearly 11% despite... Medical Equipment, Supplies & Distribution…
Latham Advises Arsenal Medical in Acquisition by Terumo Neuro
Terumo Neuro announced it has signed an agreement to acquire Arsenal Medical Inc., a privately held, clinical-stage biomaterials company developing NeoCast™, an investigational next-generation liquid embolic technology for the treatment of…
Terumo BCT partners TrAMPoline Pharma to automate TIL therapy manufacturing
October 6, 2026 | Tuesday | News Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company advancing blood- and cell-based therapies worldwide, has entered a research collaboration with TrAMPoline Pharma and Eduardo…
Terumo Blood and Cell Technologies partners with TrAMPoline Pharma to automate TIL therapy manufacturing for solid tumors
Because TILs are derived from immune cells that have already infiltrated the tumor microenvironment, they are being explored as a promising approach for solid tumors, an area where traditional CAR-T therapies have faced biological and…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
legaldesire.com1
-
lw.com1
-
manufacturingchemist.com1
-
marketscreener.com1
-
natlawreview.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.